agents are recommended in the guidelines of major international societies such as the European Society of Cardiology (ESC)(4) the American Heart Association (AHA) and the American College of Cardiology (ACC)(5) for the treatment of mild, moderate and severe CHF, and have been clinically proven in a number of landmark clinical trials.
The COPERNICUS trial is so important because the results tell us that carvedilol can reduce the risk of death in a much broader range of patients than we previously thought possible for agents with beta blocking activity.
Coreg, approved in May 1997, is the only drug with beta blocking properties approved in the U.
Despite compelling evidence about their benefits from previous studies, beta blocking agents are dramatically under-utilized in the treatment of heart failure.
Landmark study results reported by researchers showed that the beta blocking
agent Coreg(r) (carvedilol) decreased mortality rates by 35 percent in patients with the most advanced stage of heart failure who were already taking standard therapy.
Strasbourg, France -- Strasbourg, France, June 23 /PRNewswire/ -- Patients with chronic heart failure (CHF) treated with the non-selective beta blocking agent, carvedilol (Dilatrend(r)), gained a highly significant survival benefit (17 per cent, p=0.
With more than 14,000 patient years of follow up, COMET is the largest and longest study in CHF and the first head-to-head survival study comparing two beta blocking agents in patients with CHF.